Navigation Links
Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent
Date:9/24/2010

WASHINGTON, Sept. 24 /PRNewswire/ -- OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America.

"Completion of enrollment of this study represents a significant milestone as we look to validate the potential for the Combo Stent in a clinical setting," said Al Novak, Chairman and CEO of OrbusNeich.

The primary objective of the prospective, randomized, multicenter study, called REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt), is to demonstrate safety and effectiveness of the Combo Stent compared to the TAXUS® Liberte® paclitaxel-eluting stent in patients with symptomatic, ischemic heart disease due to a stenotic lesion located in a native coronary artery. This objective will be measured in patients by a comparison of in-stent late lumen loss at nine months post-procedure.

Michael Haude, M.D., director of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, and one of the trial's principal investigators, added, "The Combo Stent has the potential to bring a unique treatment option to physicians by combining the proven Genous endothelial progenitor cell capture technology with a low dose sirolimus elution. Because the pre-clinical data demonstrate lower neointimal hyperplasia and improved endothelial coverage, we look forward to obtaining clinical confirmation of the results."

Secondary endpoints include all-cause and cardiac mortality, myocardial infarction, Major Adverse Cardiac Event (MACE) and stent thrombosis rates at 30 days, nine months and one through five years, as well as clinically driven Target Lesion Revascularization (TLR), Target Ves
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... MELVILLE, N.Y. , Nov. 21, 2014  Cardinal ... the world,s largest health care services companies, and Henry ... largest provider of health care products and services to ... that the companies have entered into a long-term strategic ... and product offerings to office-based medical practices.  This strategic ...
(Date:11/21/2014)... 20, 2014  RedRick Technologies, a provider of ... room environment guidance, has helped the new Penn ... room, which may also serve as a model ... "In line with the tenets ... Radiology,s Imaging 3.0 ™ initiative, the new ...
(Date:11/21/2014)... , Nov. 20, 2014 Depomed, Inc. (NASDAQ: ... the Piper Jaffray 26 th Annual Healthcare Conference in ... the Piper Jaffray conference is scheduled for 8:00 am EST (5:00 ... webcast, and the webcast can be accessed via the Investor Relations ... of the webcast will be archived for 30 days on the ...
Breaking Medicine Technology:Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2
(Date:11/22/2014)... AZ (PRWEB) November 22, 2014 Hastings ... with decades of experience announces providing clients with the ... The firm offers clients a flexible, intuitive and easy ... combined with having access to Google + allows clients ... order to make a more informed decision when retaining ...
(Date:11/22/2014)... Petersburg, FL (PRWEB) November 22, 2014 ... Kitchen Innovations are pleased to announce that Ashley ... the Thanksgiving #PayItForward contest. , Ms. Lombardo entered ... from Kitchen Innovations. She wrote of how her friend ... young daughters as a single mom. Despite medical bills ...
(Date:11/22/2014)... 2014 Sandbridge Capital, a private ... the consumer brand sector, acquired a minority stake ... used to help fund BackJoy’s global growth and ... its proprietary apparel and footwear lines. Sandbridge Capital ... of Directors. , BackJoy is a high-growth health ...
(Date:11/22/2014)... Viejo, California (PRWEB) November 22, 2014 Developers ... announced a new plugin entitled FCPX 3D Model bringing the ... “FCPX 3D Model allows users to add obj files to ... Pixel Film Studios. “Blurring the line between professional and armature, ... Model from Pixel Film Studios allows Final Cut Pro X ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Wright & ... AndroGel side-effects lawsuits have been scheduled between October ... Northern District of Illinois. U.S. District Judge Matthew F. ... a Case Management Order (CMO) on November 6, 2014 ... for attorneys to submit documents and other activities in ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
... the University of Copenhagen have collaborated with the company ... of the brain,s complex communication system. The discovery could ... for patients with psychiatric disorders. The results were recently ... to the puzzle of brain functionNew knowledge challenges established ...
... (HealthDay News) -- A calcium test performed with the assistance ... likelihood that certain patients at moderate risk of heart problems ... The test to detect coronary calcium can help physicians ... their cardiovascular risks, the study authors explained. At ...
... Albany, NY (August 18, 2011) AMRI (NASDAQ: ... award from the National Institutes of Health (NIH)/National ... provide chemistry and other drug discovery technologies in ... (MCNP), part of the NIH Blueprint Neurotherapeutics Network. ...
... Reporter , THURSDAY, Aug. 18 (HealthDay News) -- The 2011-12 ... last year,s, but that doesn,t mean it,s OK to skip ... Disease Control and Prevention warn. "All people aged ... Bridges, an associate director for adult immunization at the CDC,s ...
... , THURSDAY, Aug. 18 (HealthDay News) -- Flu vaccination ... recent years but are still below the 2020 national ... the U.S. Centers for Disease Control and Prevention also ... All health care personnel should get an annual ...
... they are more like complex societies, each with a ... Understanding this "social structure" of tumors is critical for ... may be sensitive to different drugs. A common theory ... all cancer cells descend from special self-renewing cancer stem ...
Cached Medicine News:Health News:New piece to the puzzle of brain function 2Health News:Test for Calcium Buildup May Spot Heart Attack, Stroke Risk 2Health News:AMRI receives NIH contract award for development of pre-clinical drug candidates 2Health News:Don't Skip This Year's Flu Shot: CDC 2Health News:Flu Shot Rates Low for Health Workers, Moms-to-Be: CDC 2Health News:Cancer stem cells made, not born 2Health News:Cancer stem cells made, not born 3
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 4.0mm....
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Medicine Products: